- ConsumersReduces compliance costs for creditors and consumer reporting agencies by avoiding new rule implementation.
- Potential benefitPreserves creditor access to medical-related information for underwriting, fraud detection, and risk modeling.
- LendersSupports small lenders by avoiding new operational burdens and technology upgrades.
Disapprove CFPB Prohibition on Creditors and Consumer Reporting Agencies…
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
This joint resolution invokes the Congressional Review Act to disapprove and nullify a Bureau of Consumer Financial Protection (CFPB) rule titled "Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V)" (90 Fed. Reg. 3276, Jan 14, 2025).
Progressives emphasize medical privacy and anti-discrimination protections
Relative to its intended legislative type, this bill is a concise, standard Congressional Review Act disapproval resolution that clearly identifies the targeted rule and states the dispositive legal effect.
This joint resolution invokes the Congressional Review Act to disapprove and nullify a Bureau of Consumer Financial Protection (CFPB) rule titled "Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V)" (90 Fed.
Reg. 3276, Jan 14, 2025).
If enacted, the resolution would strip that CFPB rule of legal effect and prevent it from taking force.
Content is narrow and procedurally eligible for CRA fast-track, so plausible if Congressional majority and executive branch align; otherwise unlikely.
Relative to its intended legislative type, this bill is a concise, standard Congressional Review Act disapproval resolution that clearly identifies the targeted rule and states the dispositive legal effect.
Progressives emphasize medical privacy and anti-discrimination protections
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- ConsumersAllows creditors and reporting agencies to use medical information, increasing consumer privacy risks.
- Potential burdenRaises discrimination risks against people with medical conditions in credit decisions or pricing.
- ConsumersRolls back consumer protections the Bureau designed to limit sensitive data misuse.
Why the argument around this bill splits.
Progressives emphasize medical privacy and anti-discrimination protections
Likely opposes the resolution because it nullifies a CFPB rule that restricts use and sharing of medical information by creditors and consumer reporting agencies.
Views this as a rollback of consumer privacy and anti-discrimination protections for sensitive health data.
Takes a cautious, mixed view.
Sees tradeoffs between consumer privacy protections and regulatory costs or unintended credit market effects.
Favors a targeted fix or careful cost-benefit review rather than an outright, permanent disapproval if possible.
Likely supports the resolution as regulatory relief and a check on CFPB rulemaking.
Views disapproval as protecting lender flexibility and preventing an overbroad restriction on credit underwriting and reporting practices.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and procedurally eligible for CRA fast-track, so plausible if Congressional majority and executive branch align; otherwise unlikely.
- Congressional majority support and cohesion
- Administration's position and possible veto threat
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Progressives emphasize medical privacy and anti-discrimination protections
Content is narrow and procedurally eligible for CRA fast-track, so plausible if Congressional majority and executive branch align; otherwis…
Relative to its intended legislative type, this bill is a concise, standard Congressional Review Act disapproval resolution that clearly identifies the targeted rule and states the dispositive legal effect.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.